Adial Pharmaceuticals appoints Vinay Shah as CFO effective Nov 16, 2024; Joseph Truluck resigns

ADIAL PHARMACEUTICALS, INC.

CFO Joseph Truluck resigns effective Nov 15, 2024; will serve as consultant through Mar 31, 2025.
Vinay Shah appointed CFO effective Nov 16, 2024, with a 3-year employment term.
Shah receives $315K annual base salary, up to 30% discretionary bonus, and 40,000 stock options.
Shah previously served as CFO at Virpax (VRPX) and Aravive (ARAV), with over 25 years industry experience.
Truluck's resignation was not due to any disagreement with the company over operations or accounting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Truluck

Chief Financial Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2024-11-15
Successor: Vinay Shah
Filed: November 5, 2024, 6:59 PM ET

he would serve until November 15, 2024 as the Company’s Chief Financial Officer

Appointed

Vinay Shah

Chief Financial Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2024-11-16
Filed: November 5, 2024, 6:59 PM ET

On November 1, 2024, the Company’s board of directors effective November 16, 2024 appointed Vinay Shah, age 61, as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Joseph Truluck resigned as Chief Financial Officer at ADIAL PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

he would serve until November 15, 2024 as the Company’s Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vinay Shah was appointed as Chief Financial Officer at ADIAL PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 1, 2024, the Company’s board of directors effective November 16, 2024 appointed Vinay Shah, age 61, as the Company’s Chief Financial Officer.

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-094344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.